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Abstract
Background: Catheter-related bladder discomfort (CRBD) is a common distressing symptom complex during the
postoperative period, especially after urologic procedures with a relatively greater size urinary catheter. In this study,
we will enroll male patients undergoing elective prostate surgery with urinary catheterization under general
anesthesia, and we will compare the efficacy of pudendal nerve block (PNB) and intravenous tramadol in CRBD
prevention.
Methods/design: This trial is a prospective, randomized controlled trial that will test the superiority of bilateral PNB with
0.33 % ropivacaine compared with intravenous tramadol 1.5 mg/kg for CRBD prevention. A total of 94 male patients
undergoing elective prostate surgery with urinary catheterization after anesthesia induction will be randomized to
receive either bilateral PNB with 0.33 % ropivacaine (the PNB group) or intravenous tramadol 1.5 mg/kg (the tramadol
group) after the completion of surgery. The primary outcome is the incidence of CRBD. The most important secondary
outcome is the severity of postoperative CRBD, and other secondary outcomes include Numeric Rating Scale (NRS) score
for postoperative pain; incidence of postoperative side effects such as postoperative nausea/vomiting, sedation,
dizziness, and dry mouth; postoperative requirement for tramadol as a rescue treatment for CRBD and sufentanil as a
rescue analgesic for postoperative pain; and NRS score for acceptance of an indwelling urinary catheter.
Discussion: This trial is planned to test the superiority of PNB with 0.33 % ropivacaine compared with intravenous
tramadol 1.5 mg/kg. It may provide a basis for a new clinical practice for the prevention of CRBD.
Trial registration: ClinicalTrials.gov identifier NCT02683070. Registered on 11 February 2016.
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Background
Catheter-related bladder discomfort (CRBD) in patients
with urinary catheterization during operation is frequently
reported in the postanesthesia care unit (PACU) [1]. It is a
distressing symptom complex characterized as a burning
sensation or stabbing pain with an urge to void or as dis-
comfort from the suprapubic area to the urethra [2]. The
condition of CRBD may aggravate postoperative pain, in-
crease the incidence of postoperative complications, and
result in prolongation of hospital stay [2–4].
The mechanism of CRBD is mediated by type 3 muscar-
inic receptor activation, which increases acetylcholine
release and then causes the detrusor muscles of the blad-
der to contract involuntarily [5]. Antimuscarinic agents,
including tramadol, tolterodine, oxybutynin, pregabalin,
and ketamine, have been applied to treat CRBD in clinical
practice [6–10]. However, in spite of their beneficial effect
on CRBD, systemic administration of these agents is asso-
ciated with side effects such as nausea or vomiting, sed-
ation, dizziness, or other unpleasant complications, which
may result in reduced quality of recovery. It is important
in clinical practice to establish an effective treatment for
CRBD with reduced adverse effects.
Anatomically, the afferent nerves of the urethra and
bladder triangle are derived from sacral somatic nerves
(S2–S4 segment) [5] and theoretically, prevention of CRBD
should be achieved by blocking these nerves. The pudendal
nerve, the main nerve of the perineum, is derived from the
ventral rami of the second, third, and fourth sacral spinal
nerves; innervates the urethral sphincter and muscles of
the perineum and pelvic floor; and provides sensation to
the penis in males and the clitoris in females, as well as to
the urethra and bladder triangle [11, 12]. Clinically, puden-
dal nerve block (PNB) has been applied for analgesia of
labor and/or vaginal birth [13], vaginal repair [14], sphinc-
terotomy [15], and treatment of pudendal neuralgia [16],
and the safety and effectiveness of PNB have been identi-
fied [12–16]. On the basis of the anatomical and physio-
logical proof for nerve innervation, with the support of
clinical experience, we designed this trial with the hypoth-
esis that PNB has a CRBD-reductive effect with less side ef-
fects related to systemic administration of antimuscarinic
agents than PNB with ropivacaine and intravenous trama-
dol, and we aim to provide a novel and effective way to re-
duce the incidence of CRBD and with a better outcome.
Methods/design
Design
The PNB trial (ClinicalTrials.gov identifier NCT02683070)
is an investigator-initiated, prospective, randomized con-
trolled trial that will test the superiority of PNB with 0.33 %
ropivacaine to intravenous tramadol 1.5 mg/kg for reduc-
tion of CRBD. It will be conducted in accordance with the
principles outlined in the Declaration of Helsinki and will
follow the Consolidated Standards of Reporting Trials
(CONSORT) statement (http://www.consort-statemen-
t.org/). A brief flow diagram of the PNB trial is provided in
Fig. 1, and a populated Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) checklist is
provided in Additional file 1.
The study has no external financial sponsor, and there
are no conflicts of interest in the study design, data col-
lection, analysis, or results interpretation. Before we start
the study, all of the participants, including physicians,
interns, and nurses, will be educated and trained, and
some of them will be responsible for follow-up. After
the completion of this trial, the role of the participants,
including trial designer, trial executor, and staff respon-
sible for follow-up, will be stated in detail.
Sample size calculation
The incidence of CRBD has been reported to range from
47 % to 90 % according to different types of surgery, and
male sex has been identified to be an independent pre-
dictor in previous studies [1, 3]. We investigated 367 male
patients in the PACU of the Department of
Anesthesiology, West China Hospital, from 21 June 21 to
17 July 2015 and found that 56.1 % (206 of 367) of them
complained of CRBD. On the basis of this information, a
difference of 25 % (e.g., 30 % vs. 55 %) in the incidence of
CRBD values between two treatment groups is considered
to be clinically important. The sample size was calculated
Fig. 1 The pudendal nerve block trial algorithm
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to compare two proportions with two-sample noninferior-
ity or superiority; assuming the difference between two
groups at a 5 % significance level and a power of 0.80, 37
patients in each group are required for a comparison
within the groups. Considering an estimated 20 % dropout
rate, 47 patients in each group, and 94 patients in total,
are required in this study.
Recruitment
A total of 94 patients undergoing elective prostate surgery
in lithotomy position with urinary catheterization (16-
French Foley catheter) while under general anesthesia will
be enrolled at West China Hospital of Sichuan University.
Randomization and blinding
A biostatistician in the Department of Anesthesiology,
West China Hospital of Sichuan University, will perform
randomization using SAS version 9.1 software (SAS In-
stitute, Cary, NC, USA). For the purpose of blinding, the
results of randomization and group allocation will be
concealed in a nontransparent envelope and kept by a
research assistant. After confirmation of the patient’s en-
rollment, the investigator will call the research assistant
to get the allocated group and intervention by opening
the envelope. The investigators, research assistant, and
responsible physicians will not be blinded to the treat-
ment assignment, and the patients, staff responsible for
follow-up, and statisticians will be blinded to it.
Study organization
The study will be supervised for data completeness and
accuracy by the Department of Anesthesiology, West
China Hospital, and RL will be responsible for data
monitoring and alerting for serious complications. The
data safety and monitoring board will be involved for
the duration of the trial. There are no stop rules in this
pilot study, and no preliminary analysis will be per-
formed before the completion of this study.
Enrollment criteria
The following are the inclusion criteria:
 Male patients aged 18–80 years
 Undergoing elective prostate surgery in lithotomy
position with urinary catheterization while under
general anesthesia
The exclusion criteria are as follows:
 History of bladder dysfunction, including overactive
bladder, which is defined as urinary frequency more
than three times in the night or more than eight
times in 24 h [5]; neurogenic bladder; and bladder
outflow obstruction
 Coagulation disorders
 History of vestibular dysfunction
 History of substance abuse
 Known allergy to ropivacaine, tramadol, or any
other anesthetic agent
 History of postoperative delirium
 Impairment of cognitive function
Interventions
In the PNB group, bilateral PNB with 30 ml of 0.33 %
ropivacaine (15 ml for each side) will be performed after
the operation is finished. In the tramadol group, intra-
venous tramadol 1.5 mg/kg will be administered after
the operation is finished.
Outcome measures
All patients will be extubated after completion of the op-
eration and then transferred to the PACU for outcome
evaluation. Patients will be asked directly and observed
by staff responsible for follow-up who were blinded to
the group assignments for outcomes at 0, 0.5, 1, 2, 4,
and 6 h after patient arrival in the PACU and after ex-
traction of the urinary catheter. A questionnaire de-
signed to collect the outcome data is shown in Table 1.
Primary outcome
The primary outcome is the incidence of postoperative
CRBD.
Secondary outcomes
The following are the secondary outcomes of interest in
the trial:
1. The most important secondary outcome is the severity
of postoperative CRBD, which will be assessed with a
4-point scale as follows: 0 = no CRBD; 1 =mild CRBD,
existing only upon asking about it; 2 =moderate CRBD,
stated by the patient spontaneously; and 3 = severe
CRBD, demonstrated by behavioral response such as
strong vocal responses or attempting to pull out the
catheter [2]. When the severity of CRBD is evaluated
as 2 or 3, the patient will be administered intravenous
tramadol 1.5 mg/kg as a rescue treatment for bladder
discomfort reduction [6], and postoperative tramadol
requirement will be recorded and compared.
2. Postoperative pain will be evaluated by the patients
themselves using a single 11-point Numeric Rating
Scale (NRS), which ranges from 0 to 10, where 0
indicates “no pain” and 10 represents “worst imaginable
pain” [17]. If the patient complains about pain with an
NRS score greater than 4, intravenous sufentanil 5 μg
will be administered as a rescue analgesic treatment,
and postoperative sufentanil requirement will be
recorded and compared.
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Table 1 Questionnaire for pudendal nerve block trial outcome evaluation
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3. Postoperative side effects will be recorded and
analyzed. These include postoperative nausea/
vomiting, sedation, dizziness, and dry mouth.
Sedation will be assessed using the Ramsay Sedation
Scale (1 = anxious, agitated, or restless; 2 =
cooperative, oriented, and tranquil; 3 = responds to
command, asleep; 4 = brisk response to light
glabellar tap or loud noise; 5 = a sluggish response to
light glabellar tap or loud noise; and 6 = no
response) [18]. Patients with a Ramsay Sedation
Scale score greater than 4 will be considered
sedated.
4. Acceptance of the indwelling urinary catheter will be
evaluated by using an NRS score ranging from 0
(totally not acceptable) to 10 (totally acceptable)
after extraction of the catheter.
5. The incidence of complications related to PNB,
including hemorrhage and/or hematoma, infection
of injection site, and accidental systemic
administration of ropivacaine, which will be
recorded and evaluated for overall safety of this
technique, will be recorded.
Statistical analysis
An intention-to-treat analysis will be performed to com-
pare all primary and secondary outcomes with the use of
SPSS version 18.0 software (SPSS, Inc., Chicago, IL,
USA). Demographic data will be compared using Stu-
dent’s t test. The incidence of CRBD and postoperative
side effects will be analyzed by chi-square test. The se-
verity of CRBD will be analyzed using Fisher’s exact test.
NRS scores for postoperative pain and acceptance of the
indwelling urinary catheter will be analyzed using the
Mann-Whitney U test. Postoperative tramadol and
sufentanil requirements will be analyzed using the Z test.
p < 0.05 will be considered to be statistically significant.
Discussion
PNB, a local anesthetic technique, has been applied
widely in patients undergoing perineal and vaginal sur-
gery [13–15], for relief of pudendal neuralgia [16], and
for treatment of detrusor-sphincter dyssynergia and ex-
ternal urethral sphincter hypertonicity in patients with
spinal cord injury [19, 20]. In addition, a combination of
pudendal and periprostatic nerve block has been re-
ported to improve pain reduction during transperineal
prostate biopsy compared with periprostatic anesthesia
only [21]. On the basis of findings reported in the litera-
ture and the neural anatomy that sensation of the blad-
der triangle and urethra provided by the pudendal nerve
derived from sacral nerves S2–S4, we hypothesize that
PNB could reduce the incidence of CRBD as well as side
effects due to less nerve-related side effects associated
with nerve block than intravenous systemic administra-
tion of antimuscarinic agents.
As a weak opioid with a potent antimuscarinic effect,
tramadol is commonly used for postoperative pain relief
and chronic pain management [22, 23], and it is re-
ported to halve the incidence of postoperative CRBD [6]
and is administered to patients with severe CRBD as a
rescue treatment [9]. Therefore, we chose intravenous
tramadol administration as the control and will test the
superiority of PNB with 0.33 % ropivacaine to tramadol
1.5 mg/kg in CRBD prevention. On the basis of a previ-
ous study [9], intravenous tramadol 1.5 mg/kg will be
given to the patients with moderate to severe CRBD as a
rescue treatment to relieve their bladder discomfort.
During the execution of the PNB trial, all eligible pa-
tients will receive the allocated intervention while under
general anesthesia, and the research nurses responsible
for follow-up and the statistician will not be aware of to
which group the patient or data belongs, so the patients,
the research nurses, and the statistician will be blind to
the group allocation. A 16-French Foley catheter will be
inserted into the patients in the present study to test the
effects of CRBD prevention because this diameter of the
Foley catheter is superior to the 18-French diameter and
has been reported to be an independent predictor re-
sponsible for moderate or severe CRBD [1]. Sterilized li-
quid paraffin will be applied for catheterization for
prevention against urethral mucosal injury, but local an-
esthetics will not be spread onto the surface of catheter,
to minimize other confounding factors related to CRBD.
Furthermore, although we will test the superiority of
PNB with ropivacaine to intravenous tramadol in CRBD
prevention, we do not aim to deny the beneficial effects
of antimuscarinic agents to relieve CRBD. Instead, we
will use tramadol as a rescue treatment to reduce blad-
der discomfort in the PACU.
There are several limitations of this trial. First, with re-
gard to the study design, because of different routes of
administration (nerve block vs. intravenous), the investi-
gator and responsible physicians will not be blind to
group allocation. Second, PNB will be performed with
the patient in lithotomy position in current clinical prac-
tice, so we will choose patients undergoing prostate sur-
gery placed in the lithotomy position. Therefore, a
limitation exists in the application of PNB to patients
undergoing other operations in the supine, prone, or
other position, and other routes of PNB should be ex-
plored in the next step. Third, for patients undergoing
medical procedures requiring urinary catheterization
without any surgical intervention, the risks and benefits
of PNB should be balanced, and this aspect will not be
discussed in this study. In addition, CRBD is a very sub-
jective feeling, and it can be defined only semiquantita-
tively on the basis of the patient’s own complaint and
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the physician’s judgment. That is why the incidence of
CRBD varies in different articles [1, 3], and we will try
our best to get an accurate measurement of CRBD by
careful follow-up.
In summary, this trial is designed to find an optimal
clinical practice for CRBD reduction by performing a su-
periority test for the PNB with 0.33 % ropivacaine com-
pared with intravenous tramadol 1.5 mg/kg.
Trial status
The study is not yet recruiting as of the date of
publication.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 checklist: recommended items to
address in a clinical trial protocol and related documents. (DOC 117 kb)
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